Site notifications

Sub menu

 
 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

1073 result(s) found, displaying 176 to 200

  • AusPAR: Comirnaty

    Australian Public Assessment Report (AusPAR)
    AusPAR for COMIRNATY (tozinameran) for the prevention of COVID-19.

  • AusPAR: Lutetium (177Lu) chloride

    Australian Public Assessment Report (AusPAR)
    AusPAR for Lutetium (177Lu) chloride (lutetium (177Lu) chloride) for the treatment of non-resectable or metastatic neuroendocrine tumours expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.

  • AusPAR: Zeposia

    Australian Public Assessment Report (AusPAR)
    AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.

  • AusPAR: Libtayo

    Australian Public Assessment Report (AusPAR)
    New AusPAR for LIBTAYO (cemiplimab) as first-line treatment of adult patients with non-small cell lung cancer.

  • AusPAR: Pegcetacoplan

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Empaveli (pegcetacoplan) for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria.

  • AusPAR: Tepmetko

    Australian Public Assessment Report (AusPAR)
    Tepmetko (tepotinib) for treatment of non-small cell lung cancer with MET exon 14 skipping alterations.

  • AusPAR: Tecentriq

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.

  • AusPAR: Brukinsa

    Australian Public Assessment Report (AusPAR)
    Brukinsa (zanubrutinib) for the treatment of of adult patients with Waldenström’s macroglobulinaemia

  • AusPAR: Brukinsa

    Australian Public Assessment Report (AusPAR)
    Brukinsa (zanubrutinib) for the treatment of adult patients with mantle cell lymphoma

  • AusPAR: Nextstellis

    Australian Public Assessment Report (AusPAR)
    Nextstellis (estetrol monohydrate and drospirenone) for the prevention of pregnancy

  • AusPAR: Spikevax

    Australian Public Assessment Report (AusPAR)
    Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older

  • AusPAR: Tivicay and Tivicay PD

    Australian Public Assessment Report (AusPAR)
    TIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.

  • AusPAR: Nuvaxovid

    Australian Public Assessment Report (AusPAR)
    Nuvaxovid (SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for prevention of COVID-19 in individuals 12 years of age and older.

  • AusPAR: Crysvita

    Australian Public Assessment Report (AusPAR)
    Crysvita (burosumab) for the treatment of X-linked hypophosphataemia (XLH)

  • AusPAR: Verquvo

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Verquvo (vericiguat) as addition to standard of care therapy for the treatment of symptomatic chronic heart failure.

  • AusPAR: VeraSeal

    Australian Public Assessment Report (AusPAR)
    VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.

  • AusPAR: Trastuzumab deruxtecan

    Australian Public Assessment Report (AusPAR)
    Enhertu (trastuzumab deruxtecan) for treatment of unresectable or metastatic HER2 positive breast cancer.

  • AusPAR: Nuvaxovid homologous booster

    Australian Public Assessment Report (AusPAR)
    Nuvaxovid homologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Nuvaxovid heterologous booster

    Australian Public Assessment Report (AusPAR)
    Nuvaxovid heterologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Bevacizumab

    Australian Public Assessment Report (AusPAR)
    Bevacip/Bevaciptin (bevacizumab) for the treatment of types of cancer.

  • AusPAR: Finerenone

    Australian Public Assessment Report (AusPAR)
    Kerendia (finerenone) for the treatment of progressive decline of kidney function in adults.

  • AusPAR: Deutetrabenazine

    Australian Public Assessment Report (AusPAR)
    AUSTEDO (deutetrabenazine) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adult.

  • AusPAR: Remdesivir

    Australian Public Assessment Report (AusPAR)
    New AusPAR for VEKLURY (remdesivir ) for the treatment of coronavirus disease 2019 in paediatric and adult patients.

Help us improve this page